Company: MIRA
Filing Date: 2025-06-17
Form Type: PREM14A
Source: 0001641172-25-015340
Chunk: 48

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-17
Form: PREM14A
Chunk 48
---
. At such point, SKNY’s owners and executives had considered separately and independently listing its shares on the Nasdaq Stock Exchange in 2025.

In February 2025, several holders of shares of SKNY spoke with Erez Aminov, CEO of MIRA about the possibility of SKNY becoming a wholly-owned subsidiary of MIRA, and forgo its planned stand-alone public offering. These discussions focused on MIRA’s interest in acquiring SKNY to strengthen and expand its drug development pipeline. MIRA believed that the acquisition of SKNY, particularly due to the potential of SKNY-1, would enhance shareholder value. Given the overlapping relationships and common interests between MIRA and MIRALOGX, conversations regarding the proposed Merger were frequent, direct, and collaborative. See “Interests of the MIRA Directors, Executive Officers and Affiliate Shareholders in the Merger” on page 31 of this proxy statement for additional details.

On March 10, 2025, MIRA conducted an introductory call with Moore Financial Consulting Ltd. (“Moore”) regarding conducting valuations of MIRA and SKNY for purposes of determining the Exchange Ratio to be used in the Merger based on the relative valuations of MIRA and SKNY.

On March 14, 2025, MIRA engaged Moore to conduct a valuation of MIRA and SKNY for determination of the Exchange Ratio.

On March 17, 2025, a first draft of a Binding Letter of Intent (LOI) was circulated between MIRA and SKNY

On March 18, 2025, after significant information discussion, Kelly Stackpole was appointed as Chief Executive Officer of SKNY and continued on behalf of SKNY to negotiate the terms of the Merger with MIRA.

On March 19, 2025 a revised draft of the LOI was circulated between MIRA and SKNY.

On March 19, 2025, the MIRA Board held a meeting to discuss the LOI. Mr. Aminov provided a presentation on SKNY’s business and explained the potential synergies between the two companies and market potential of SKNY-1. Mr. Aminov also explained to the MIRA Board the conflicts of interests involved in the Merger. The terms of the LOI and the SKNY-1 Licensing Agreement were also discussed and reviewed. The MIRA Board approved the Merger and the terms of the LOI.

At the March 19, 2025 meeting of the MIRA Board, the